MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Biocept DPO Ratio 2011-2026 | BIOC
Annual DPO Ratio Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.3 | 75.4 | 143 | 66.9 | 74.1 | 49.6 | 50.7 | 50.2 | 108 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 143 | 49.6 | 74.9 |
Quarterly DPO Ratio Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.7 | 46 | - | 62.2 | 73.4 | 67.7 | - | 52 | 79.5 | 79.3 | - | 130 | 303 | 161 | 63.9 | 64.8 | 68.7 | 71.1 | 76.4 | 75 | 68.9 | 62 | 49.1 | 46.6 | 48.9 | 47.8 | 46.1 | 46.7 | 52.5 | 49.3 | 45.2 | 49.8 | 57 | 50.6 | 95.2 | 109 | 163 | 151 | - | 227 | 237 | 128 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 303 | 45.2 | 88.4 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
106 | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Danaher Corporation
DHR
|
66.4 | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
70.4 | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 11.38 | 6.36 % | $ 323 M |  Israel |
 |
IQVIA Holdings
IQV
|
126 | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Myriad Genetics
MYGN
|
42 | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
20.7 | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Precipio
PRPO
|
53 | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
67.3 | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
83.6 | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Soleno Therapeutics
SLNO
|
130 | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
ENDRA Life Sciences
NDRA
|
1.65 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Illumina
ILMN
|
56.3 | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
Thermo Fisher Scientific
TMO
|
49.3 | $ 579.45 | -0.69 % | $ 221 B | USA |
 |
Trinity Biotech plc
TRIB
|
163 | $ 0.79 | -3.54 % | $ 61.9 M |  Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 173.53 | -1.12 % | $ 19.3 B | USA |
 |
Twist Bioscience Corporation
TWST
|
12.5 | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 182.22 | -0.43 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
27 | $ 676.53 | -0.85 % | $ 55.8 B | USA |